However, IFNα subtypes likely provide beneficial effects as well since a separate study showed that prophylactic or therapeutic administration (i.n.)of an adenoviral vector expressing IFNα enhanced survival after pneumococcal infection and decreased lung and spleen bacterial burden (149). This evidence concerns the gene IFNA1 and pneumococcal infection.